To exclude the potential impact of IDH mutations on our immunological classification of gliomas, we separated gliomas into IDH-wildtype and IDH-muted groups and compared the immune signatures between the three immune subtypes within both groups, respectively. The gene discussed is IDH1; the disease is central nervous system cancer.